Expert of the National High-level Talent Program, committee member of the National Major Scientific and Technological Special Project for “Significant New Drugs Development”, Special Expert of Zhejiang Province, Doctor of Medicine (M.D.) from the University of Arkansas (U.S.), U.S.-certified pathologist, Deputy to the 12th and 13th National People's Congress, member of the 14th Chinese People's Political Consultative Conference, member of the Standing Committee of All-China Federation of Returned Overseas Chinese, Deputy Director of the Biological and Medical Subcommittee of the Committee of Specially Appointed Experts, Deputy Chairman of Zhejiang All-China Federation of Returned Overseas Chinese, Director of the Central Financial Affairs Committee of the Chinese Peasants’ and Workers’ Democratic Party, Deputy Director of Zhejiang Provincial Committee, Vice President of China Pharmaceutical Industry Research and Development Association (SINO-PhIRDA), President of Zhejiang Pharmaceutical Association. 

In 2003, Dr. Ding founded Betta Pharmaceuticals Co., Ltd., and led the team to successfully develop China's first small-molecule anti-cancer targeted therapy - Icotinib, the first  new drug domesticallydeveloped for the treatment of advanced NSCLC with ALK mutations - Ensartinib, and the first bevacizumab biosimilar in Zhejiang - MIL60. He has built a leading R&D and commercialization platform for anti-cancer targeted therapies, presided and participated in 13 National Major Scientific and Technological Special Projects for “Significant New Drugs Development”, applied for 207 patents and published 53articles. In light of his outstanding contributions, Dr. Ding has won the First Prize of National Science Progress Award as the main contributor, the Gold Prize of China Patent Award, China Grand Awards for Industry, National Innovation Award, National Outstanding Professional and Technical Personnel, National Outstanding Science and Technology Workers, "Top 10" of Overseas Chinese, Zhejiang Province Science and Technology Major Contribution Award and other honors.

Hong Kong University of Science and Technology Executive MBA. He has worked in the orthopedics division at Beijing Tongren Hospital and has held senior management positions in multiple medical institutions and leading pharmaceutical companies, such as Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, AstraZeneca, and MSD. With nearly 30 years’ experience in establishing drug promotion channels and improving drug accessibility, he has a significant impact on promoting anti-cancer drugs and the commercialization of drugs in the Chinese market. Mr. Wan is now in charge of the oncology affairs department, the marketing department, and the market access department in Betta.

Ms. Tong received a MBA degree from Zhejiang University. She joined Betta in 2003 and has served successively as manager, director, executive secretary and VP. With rich experience in corporate operations management, particularly in capital market brand building, she was awarded "Golden Board Secretary" of a public company by Sina Finance, Outstanding Board Secretary of China's GEM-listed companies, Best Board Secretary in 2017 by Golden Bull and Outstanding Board Secretary of Zhejiang public companies in 2018. In light of her reputation in the field, she served as a member of the Standing Committee of the 8th Board Secretary Committee of the Listed Company Association of Zhejiang. Ms. Tong is in charge of the Chairman Office, the Department of Investor Relations, the Public Relations and External Liaison Office, the Department of Internal Compliance, the Department of Human Resources, the Department of Grant Application, the Department of Operation.

MBA from Macau University of Science and Technology. He has served as the president of China Construction Bank Yuhang branch, China Construction Bank Xiaoshan branch, and Shanghai Pudong Development Bank Yuhang branch. With more than 20 years of operation and management experiences in the financial industry, he has amassed strong communication, coordination, and team management skills. He has led or participated in multiple high-quality equity investments and M&A projects. Mr. Fan is in charge of the finance and investment departments.

Graduated from Bethune Medical University. He has worked for the Institute of Hematology, Chinese Medical College, and held management positions in multinational pharmaceutical companies’ China division such as Roche and Pfizer. With nearly 15 years of team management experience, she has amassed excellent skills in communication, coordination, resource integration and drug brand promotion. She has an in-depth understanding and knowledge of promoting international and domestic anti-tumor drugs, especially for innovative drugs in China. Ms. Shi is in charge of oncology business department.

Master of Public Health from Hebei Medical University. He has studied at Duke University and Emory University in the United States as a visiting scholar. He has worked for the National Medical Products Administration and held senior management positions in well-known domestic enterprises such as Mindray Medical and CStone Pharmaceuticals. With more than 20 years of of team management experience, he has amassed excellent communication, coordination, and resource integration capabilities. He has a comprehensive understanding and rich experience in the registration, review, approval and listing of drugs. Mr. Wang is in charge of the registration and project management departments.

Graduated from China Pharmaceutical University. He has served for Zhejiang Medical Products Administration and has been working in drug registration and quality management for many years. With more than 20 years’ experience in quality management, GMP certification and registration affairs in the pharmaceutical industry, he has excellent capacities in project management, guideline setting, and team management. He has presided or participated in 2 national-level major science and technology projects in new drug innovation and commercialization. Mr. Ma is in charge of the quality management department.

Kevin Ding, Chairman assistant, graduated from St. Louis University and joined Betta Pharmaceuticals in 2018.He has a comprehensive background majoring in both Biochemistry and Economics. Prior to becoming Chairman assistant, he served as a director of strategic collaboration and the executive vice general manager of Betta Dream Works. While holding those titles, Kevin Ding was directly involved with the in-licensing of MCLA-129, Ensartinib, and the promotion of Betta Amgen and other projects. Addition to these accomplishments Mr. Ding has successively reached strategic cooperations with Inventis Bio and Agenus, adding cornerstone assets to Betta’s pipeline. He helped manage the transactions of the investment department, participated in many high-quality equity investment or M & A projects, and led the equity investment in Xcovery. He has rich experience in business cooperation, personnel management and project promotion.

Mr. Xia graduated from Zhejiang University and received an EMBA degree from CEIBS. Prior to joining Betta, he has worked at Shenzhen Apecland Design Co.,Ltd and Shenzhen Huasen Architecture and Engineering Design Corporation. He joined Betta in 2012 and has served as manager and director of construction and concurrently serves as general manager of Betta Dream Works, with rich experience in engineering construction, management and investment operation and great achievements in project construction, leadership, quality control, brand building and cost control. He has established an excellent and effective investment operation service system. Mr. Xia is in charge of the Department of Operation, the Department of Construction and Betta Dream Works.

Graduated from Beijing University of Chinese Medicine. He has worked for multinational pharmaceutical companies such as Kirin Group, Sanofi-Aventis, and AstraZeneca. With more than 20 years of pharmaceutical sales experience and more than 10 years of business management experience, he has excellent communication, coordination and team management skills. Mr. Liu is in charge of the business and market access departments.

Zhejiang Provincial High-level Talent Program Expert, Bachelor of Biochemistry, Fudan University, Ph.D. in Genetics from the Chinese Academy of Sciences, postdoctoral research in genetics, cancer and diabetes at the University of Leicester and the University of Wisconsin. He has conducted drug discovery research at multinational pharmaceutical companies such as Schering-Plough, MSD, and Eli Lilly, and has led multiple drug discovery projects. He has more than 20 years of academic research and drug discovery experience in the field of diabetes and cancer, and has published more than 50 papers, including more than 20 papers as the first author or corresponding author. With strong organizational, leadership and management capabilities, he is leading multiple pharmaceutical R&D projects in Zhejiang Province. Dr.Lan is in charge of new drug discovery and pharmacology, meanwhile assists on overseas strategic business development activities.

Master of neurology from China Medical University. She has served for well-known pharmaceutical companies including Pfizer, Merck, AstraZeneca and CStone Pharmaceuticals and has been working in clinical development and management for 17 years. Ms. Li is in charge of the research, development and follow-up of clinical strategies for new drugs and the management of medical science.

VP, Head of Clinical Operating and medical affairs. Bachelor of Clinical Medicine from Norman Bethune Medical University, IMBA from Peking University. Prior to joining Betta, she worked at the Central Hospital of the Ministry of Aerospace Science and Technology. She has led the launch of multiple new drugs in senior management positions at well-know domestic and international pharma companies such as AstraZeneca, Novartis Pharmaceuticals, Merck, Covancs, ICON, EVEREST MEDICINES, and Sinobiopharma. She has 8 years of experience as a professional cardiologist and over 20 years working experiences  of clinical project management and operation. 

M.A. of Applied Biology and Ph.D. in Biofunction, National Shinshu University, Japan. He has worked in well-known biotech companies such as Metabolon and NantWorks and participated in the U.S. Cancer Moonshot 2020 project. He has worked in the field of life science research for more than 20 years, with rich experience in the design, testing, production, development of tumor biological models, and clinical research of immunology therapies. He has presided and managed multiple R&D projects, and successfully advanced numerous projects into clinical research, acting as a key developer of multiple new therapies. He has published more than 50 papers (including patents), two of which are on the cover of top-tier journals. With outstanding project management and team building capabilities, Dr. Xu is in charge of the department of immunobiology (R&D Center).

Mr. Wu received a Master’s degree in Finance from Peking University. Prior to joining Betta, Mr. Wu has dedicated to investment banking business at GUOTAI JUNAN SECURITIES (GTJA), UBS Securities Co. Limited (UBSS) and HUATAI UNITED SECURITIES. With a wealth of experience in A-share IPOs and overseas IPOs, equity refinancing, mergers and acquisitions, bond financing and other capital operations, he is in charge of the Department of Investor Relations and Chairman Office.

As a graduate of Peking University, Dr. Liu obtained his Ph.D. degree from Emory University, majoring in Organic Chemistry. He has over 20 years of experience in the pharmaceutical industry and the FDA.He held senior management positions in leading pharmaceutical companies, such as Johnson & Johnson, FDA, evinus pharmaceutical, Inc., GlaxoSmithKline, and Xiansheng pharmaceutical. He has a lot of experience in R&D management, team management, project management, CRO management, etc. He also has experience in the review of many NDAs and INDs at the FDA along with IND submission at the pharmaceutical industry. During his four-year tenure at the FDA as a CMC reviewer, he participated in the review and approval of many INDs and blockbuster NDAs, including the first FDA approved 4-in-1 fixed-dose combination (FDC) drug of Stribild for HIV treatment and the milestone HCV drug of Sovaldi from Gilead Sciences. Dr. Liu is in charge of CMC.

He received the MD degree in University of Torino (Italy) in 1992 and then completed residency in Pulmonology. After 17 years as a clinician and investigator in clinical trials for lung cancer and mesothelioma, joined GSK in 2010 as medical director on a cancer vaccine program. After that he covered leadership positions in Novartis (lead for ceritinib, ALK inhibitor), Oncolytics and Bristol Myers Squibb (nivolumab lead in SCLC and mesothelioma) till 2019 when he joined Xcovery in 2019 as Chief Medical Officer to lead ensartinib and vorolanib clinical programs. From March 2021 he became CEO of Xcovery. He was appointed as Medical Advisor of Betta in May 2021, mainly give advice and joint effort in the area of clinical development of new drugs and international collaboration.